Thorarinsdottir Elin H, Janson Christer, Aspelund Thor, Benediktsdottir Bryndis, Júlíusson Sigurður, Gislason Thorarinn, Kuna Samuel T, Pack Allan I, Keenan Brendan T
Primary Health Care of the Capital Area, Reykjavik, Iceland.
Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
J Sleep Res. 2022 Jun;31(3):e13528. doi: 10.1111/jsr.13528. Epub 2021 Dec 3.
Excessive daytime sleepiness includes both an inability to stay awake during the day and a general feeling of sleepiness. We describe different dimensions of daytime sleepiness in adults with moderate-severe obstructive sleep apnea (OSA) before and after 2 years of positive airway pressure (PAP) treatment. Using the Epworth Sleepiness Scale (score >10 defined as "risk of dozing") and Basic Nordic Sleep Questionnaire (feeling sleepy ≥3 times/week defined as "feeling sleepy"), participants were categorised into sleepiness phenotypes labelled non-sleepy, risk of dozing only, feeling sleepy only, or both symptoms. Participants repeated baseline assessments and PAP adherence was evaluated after 2 years. PAP-adherent subjects with sleepiness symptoms at both baseline and follow-up were considered persistently sleepy. Of the 810 participants, 722 (89%) returned for follow-up. At baseline, 17.7% were non-sleepy, 7.7% were at risk of dozing only, 24.7% were feeling sleepy only, and 49.9% had both symptoms. PAP adherence did not differ by baseline sleepiness phenotype. Patients with risk of dozing demonstrated greater PAP benefits for sleepiness symptoms than non-sleepy and feeling sleepy only phenotypes. Using these phenotypes, 42.3% of PAP users had persistent sleepiness; they had less severe OSA (p < 0.001), more persistent OSA symptoms and more often had symptoms of insomnia than patients in whom sleepiness resolved. Our present results, therefore, suggest that measuring the risk of dozing and the feeling of sleepiness reflect different sleepiness components and may respond differently to PAP. Patients feeling sleepy without risk of dozing may need more thorough evaluation for factors contributing to sleepiness before initiating treatment.
日间过度嗜睡包括白天无法保持清醒以及普遍的困倦感。我们描述了中度至重度阻塞性睡眠呼吸暂停(OSA)成人患者在接受两年气道正压通气(PAP)治疗前后日间嗜睡的不同维度。使用爱泼华嗜睡量表(得分>10定义为“打瞌睡风险”)和北欧基本睡眠问卷(每周困倦≥3次定义为“感到困倦”),参与者被分类为嗜睡表型,标记为不困倦、仅打瞌睡风险、仅感到困倦或两种症状都有。参与者重复进行基线评估,并在两年后评估PAP依从性。在基线和随访时都有嗜睡症状的PAP依从性受试者被认为持续嗜睡。在810名参与者中,722名(89%)返回进行随访。基线时,17.7%不困倦,7.7%仅存在打瞌睡风险,24.7%仅感到困倦,49.9%有两种症状。PAP依从性在不同基线嗜睡表型之间没有差异。与不困倦和仅感到困倦的表型相比,有打瞌睡风险的患者在嗜睡症状方面从PAP治疗中获益更大。使用这些表型,42.3%的PAP使用者存在持续嗜睡;与嗜睡症状缓解的患者相比,他们的OSA病情较轻(p<0.001),OSA症状更持续,且更常出现失眠症状。因此,我们目前的结果表明,测量打瞌睡风险和困倦感反映了不同的嗜睡成分,并且对PAP的反应可能不同。在开始治疗前,没有打瞌睡风险但感到困倦的患者可能需要对导致嗜睡的因素进行更全面的评估。